Boston Scientific

Boston Scientific Corporation has acquired the fiXate™ Tissue Band from Anulex technologies, Inc. The fiXate Tissue Band is a novel suturing device that is designed to enable quick and simple placement of a suture to help secure a spinal cord stimulator lead or pain pump catheter.

Boston Scientific Corporation has received U.S. FDA approval for its Precision Spectra Spinal Cord Stimulator System. The company is now beginning a limited launch of what it says is the world’s first and only SCS system with Illumina 3D™ software and 32 contacts.

The Left Atrial Appendage is a troublesome little design feature. It doesn’t appear to possess any purpose and can be the source of clots, especially in AF patients, leading to an attendant stroke risk. So let’s block it off? Eu regulators seem happy with that idea, U.S. less so, which again shows up our differences.

Organisers pulled the PREVAIL study into the Watchman Left Atrial Appendage occlusion device from its allotted slot in the late-breakers clinical session, as well as its associated press conference because Boston Scientific broke its embargo by releasing the data early by email.

The FDA has so far not approved Boston Scientific’s Watchman Left Atrial appendage closure device. This week’s ACC event in San Francisco sees the first sight of clinical data from the PREVAIL study which may support the theory that the device is an alternative to blood thinning therapy.

Boston Scientific’s PR machine is on top of its game, drawing attention to all the good things that will be presented in the company’s name at this years ACC meeting at the weekend.

OrbusNeich alleges that Boston Scientific has infringed two European patents covering certain novel stent designs. It claims two patents are infringed by several of Boston Scientific’s coronary stent systems, including the “PROMUS Element™”, “PROMUS Element™ Plus”, “OMEGA™ PtCr”, and “TAXUS™ Element™”.

The first patient has been treated in the Boston Scientific’s ZERO AF clinical trial to evaluate the safety and effectiveness of the Blazer® Open-Irrigated Temperature Ablation Catheter in patients with symptomatic, drug refractory paroxysmal atrial fibrillation. This international, multi-center study will include up to 472 patients at 33 sites in the United States, Europe and Asia-Pacific.

A first patient has been implanted with Boston Scientific’s new INGEVITY™ pacing leads in a clinical trial designed to establish the safety, performance and effectiveness of the leads.

Boston Scientific Corporation has received CE Mark approval and has begun the European market launch of the Precision Spectra™ Spinal Cord Stimulator (SCS) System, the world’s first and only SCS system with 32 contacts and 32 dedicated power sources.

The first patient has been enrolled in a Boston Scientific Corporation (NYSE: BSX) study comparing the WallFlex® Biliary RX Fully Covered self-expanding metal stent (SEMS) to plastic stents for the treatment of benign bile duct strictures caused by chronic pancreatitis.

Boston Scientific will feel they have stolen some solid commercial ground with the news that, in Europe they can now claim extended life from their defibrillator ranges thanks to their new battery technology.

Boston Scientific Corporation and the University of Rochester Medical Center have shown that improved programming of Boston Scientific dual-chamber ICD or CRT-D heart devices can reduce inappropriate therapy and risk of death.

Well well well. All the big players have renal denervation systems in development or already in the catalogue. Now, so does Boston Scientific with the year’s least surprising acquisition of Vessix Vascular.

It seems like he’s been there for ages… because he has. Now after a year sorting out his previous responsibilities to former employer J&J among other things, Mike Mahoney formally takes the CEO and President reigns at Boston Scientific.

Boston Scientific Corporation has announced CE Mark approval for the Synergy™ Everolimus-Eluting Platinum Chromium Coronary Stent System featuring its ultra-thin abluminal bioabsorbable polymer coating which holds the promise of reducing late adverse events.